Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic-Reference-Cited by-同舟云学术

Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic

Published:2019-01-28 Issue:1 Volume:19 Page:
ISSN:1471-2334
Container-title:BMC Infectious Diseases
language:en
Short-container-title:BMC Infect Dis

Author:

Udwadia Zarir F.,Tornheim Jeffrey A.^ORCID,Ganatra Shashank,DeLuca Andrea,Rodrigues Camilla S.,Gupta Amita

Funder

Johns Hopkins University Clinician Scientist Career Development Award

UJMT Fogarty Global Health Fellows Program

Johns Hopkins University Center for Global Health

National Institute of Allergy and Infectious Diseases

NIH/DBT RePORT India consortium

Ujala Foundation

Gilead Foundation

Wyncote Foundation

Frederick Mulder Foundation

Pogge Tong Foundation

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/content/pdf/10.1186/s12879-019-3726-8.pdf

Reference32 articles.

1. WHO: Global Tuberculosis report 2017. In. Geneva: World Health Organization; 2017.

2. WHO: Global Tuberculosis Report 2016. In., vol. 2016. Geneva, Switzerland: World Health Organization; 2016.

3. WHO: WHO treatment guidelines for drug-resistant tuberculosis. In. Geneva, Switzerland: World Health Organization; 2016: 61.

4. RNTCP: Revised National Tuberculosis Control Program Annual Status Report Unite to end TB. In. New Delhi, India: Revised National Tuberculosis Control Program; 2017: 173.

5. Census India 2011. Mumbai (Greater Mumbai) City Census 2011 data [ http://www.census2011.co.in/census/city/365-mumbai.html ].

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Resistance and Epidemiological Success of Modern Mycobacterium tuberculosis Lineages in Western India;The Journal of Infectious Diseases;2024-05-31

2. Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India;Frontiers in Pharmacology;2023-01-04

3. Swimming against the STREAM: Why STREAM 2 data cannot be easily applied to MDR-TB patients across India;Lung India;2023

4. Are We Moving Towards Development of Universal Drug Regimen for Treatment of Tuberculosis?;The Indian Journal of Chest Diseases and Allied Sciences;2022-11-07

5. Can Pan-TB shorter regimens be a promising hope for ending TB in India by 2025 in ongoing COVID-19 era?;Indian Journal of Tuberculosis;2022-10